Abstracts tagged "B-Cell Targets"

Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Omer Uludag¹, Soner Altın², Gamze Kemec², yasemin yalcinkaya³, Ahmet Gul³, Murat Inanc³ and Bahar Artim Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…
Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Ricardo Grieshaber-Bouyer¹, Jamie Haddon², Maria Gabriella Raimondo³, Carlo Tur³, Sebastian Böltz³, Tobias Dashi⁴, Melanie Hagen⁵, Andreas Wirsching³, Tobias Rathe⁴, Xuan Wu⁶, Peter Wung², Francis Kim², Yonghong Zhu⁶, Ken Song², Timothy Lu⁷ and Georg Schett⁸, ¹University Hospital Erlangen, Erlangen, Germany, ²Candid Therapeutics, San Diego, CA, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine ³- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ⁶EpimAb Biotherapeutics, Shanghai, China (People's Republic), ⁷Candid Therapeutics, San Diego, ⁸Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
Abstract Number: 2019 • ACR Convergence 2025
Incidence of Coronavirus Disease 2019 in Participants with IgG4-Related Disease Treated with Inebilizumab in the MITIGATE Study
Arezou Khosroshahi¹, Emma Culver², Wen Zhang³, Kazuichi Okazaki⁴, Yoshiya Tanaka⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone⁹, ¹Emory University, Atlanta, GA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁴Kansai Medical University Kori Hospital, Osaka, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: The potential of B-cell-depleting therapies to diminish humoral responses is recognized, but whether this leads to an increased risk of Coronavirus Disease 2019 (COVID-19)…
Abstract Number: 1198 • ACR Convergence 2025
Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
Christina Duesing¹, Ayla Nadja Stuetz², Andrea-Hermina Györfi³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Gamal Chehab⁶, Jutta Richter⁷, Marie Celine van Saan⁸, Bilgesu Safak Tümerdem², Alexandru-Emil Matei⁹, Bjoern Buehring¹⁰, Ricardo Grieshaber-Bouyer¹¹, Melanie Hagen¹², Georg Schett¹³, Wolfgang Merkt¹⁴ and Jörg Distler¹⁵, ¹Klinik für Rheumatologie, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁷Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰Bergisches Rheuma-Zentrum, Wuppertal, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁴University Hospital Düsseldorf, Düsseldorf, Germany, ¹⁵University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Treatment of anti-synthetase syndrome (ASyS) presents clinical challenges: myositis can lead to permanent disability and severe organ involvement is life-threatening.Methods: We treated three patients…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Liya Sisay Getachew¹, Xiaosong Wang², Zachary Wallace³, Naomi Patel⁴, Lauren O'Keeffe⁵, Madison Negron⁶, Grace Qian⁵, Alene Saavedra⁵, Kevin Mueller⁵, Natalie Davis⁷, Yijia Li⁸, Manish Choudhary⁵, Julie Boucau³, Brooke Leeman⁵, Gregory Edelstein⁵, Owen Glover³, Yumeko Kawano⁵, Rinki Deo⁵, Caitlin Marino³, Zahra Reynolds³, Karry Su³, Chase Mandell³, Eliza Passell³, Mamadou Barry³, Andrew Alexandrescu³, Dibya Ghimire³, Mriganka Mandal⁹, Tammy Vyas³, Sarah Hammond³, Jatin Vyas³, Jacob Lemieux³, Mark Siedner³, Amy Barczak³, Jonathan Li³ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Harvard Extension School, Medford, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸University of Pittsburgh, Pittsburgh, ⁹Dana-Farber Cancer Institute, Boston
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…
Abstract Number: 1838 • ACR Convergence 2025
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Valerie Devauchelle¹, Swati Ghanshani², CAROLE SIPS³, Rainer Hillenbrand³, Carol Lau⁴, Wolfgang Hueber⁵, Claire Bonal³ and Stephen Oliver⁶, ¹UBO, Brest, France, ²Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ³Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 0244 • ACR Convergence 2024
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
Pei-Hsinq Lai¹, Cheng-Hsun Lu² and Song-Chou Hsieh³, ¹Taipei City Hospital, Taipei, Taiwan (Republic of China), ²National Taiwan University Hospital, Taipei, Taiwan, ³National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
Abstract Number: 1396 • ACR Convergence 2024
Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Samuel Bitoun¹, Bineta Ly², Audrey Paoletti², Catherine Menier Menier³, Marc Pallardy⁴, Bernard Maillere⁵ and Xavier Mariette⁶, and ABIRISK consortium, ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, ³1 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁴Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, ⁵CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
Abstract Number: 2074 • ACR Convergence 2024
Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy
Ivana Ilic¹ and Galina Marder², ¹Northwell, Brooklyn, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].